BlackRock Inc. acquired a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,409,023 shares of the company’s stock, valued at approximately $260,721,000. BlackRock Inc. owned 0.11% of Intellia Therapeutics as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the stock. Comerica Bank lifted its holdings in Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after buying an additional 901 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Intellia Therapeutics in the second quarter valued at about $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Intellia Therapeutics in the third quarter valued at about $30,000. Advisory Services Network LLC bought a new position in shares of Intellia Therapeutics during the third quarter worth about $33,000. Finally, Fifth Third Bancorp bought a new position in shares of Intellia Therapeutics during the first quarter worth about $38,000. 88.77% of the stock is owned by institutional investors.
Insider Buying and Selling at Intellia Therapeutics
In related news, EVP Edward J. Dulac III sold 4,677 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the transaction, the executive vice president directly owned 156,286 shares of the company’s stock, valued at $2,813,148. This represents a 2.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Michael P. Dube sold 2,641 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares of the company’s stock, valued at $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by corporate insiders.
Intellia Therapeutics Stock Performance
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80). The company had revenue of $7.66 million during the quarter, compared to the consensus estimate of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The company’s quarterly revenue was down 46.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.98) EPS. Research analysts predict that Intellia Therapeutics, Inc. will post -3.21 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts recently commented on NTLA shares. Sanford C. Bernstein lifted their price objective on Intellia Therapeutics from $13.00 to $17.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Evercore upgraded shares of Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price target for the company in a report on Friday, August 7th. Citigroup restated a “market outperform” rating on shares of Intellia Therapeutics in a research report on Tuesday. Wolfe Research lowered shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price objective on the stock. in a research note on Wednesday, July 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have issued a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, Intellia Therapeutics presently has an average rating of “Hold” and an average price target of $21.15.
Check Out Our Latest Stock Report on Intellia Therapeutics
About Intellia Therapeutics
Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.
Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.
Featured Articles
- Five stocks we like better than Intellia Therapeutics
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report).
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
